Advertisement

Clinical Applications of Immunotoxins

  • Arthur E. Frankel

Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 234)

Table of contents

  1. Front Matter
    Pages i-ix
  2. I. FitzGerald, I. Pastan, J. Robertus
    Pages 1-11
  3. A. Engert, E. A. Sausville, E. Vitetta
    Pages 13-33
  4. J. E. O’Toolei, D. Esseltine, T. J. Lynch, J. M. Lambert, M. L. Grossbard
    Pages 35-56
  5. D. J. Flavell
    Pages 57-61
  6. F. M. Foss, M. N. Saleh, J. G. Krueger, J. C. Nichols, J. R. Murphy
    Pages 63-81
  7. E. H. Oldfield, R. J. Youle
    Pages 97-114
  8. A. E. Frankel, M. C. Willingham
    Pages 115-120
  9. Back Matter
    Pages 121-124

About this book

Introduction

1 2 D. FITZGERALDI, I. PASTAN , and J. ROBERTUS Introduction . . . . . . . . . . . . . I 2 Toxin Structure-Function Properties 2 2. 1 Functions. . . . . . . . . . . . . . . . . . . . . . . . 2 2. 2 Binding. . . . . . . . . . . . . . . . . . . . . . . . . 3 3 Intracellular Processing - Cleavage and Reduction . . . . . . 4 3. 1 Cytosolic Activity . . . . . . . . . . . . . . . . 5 4 Immunotoxin Design and Testing. 6 5 Conclusion. . 8 References. . . . . 8 1 Introduction While various treatment approaches for cancer include reversal of the transformed phenotype, stimulation of immune responses, inhibition of metastatic spread and deprivation of key nutrients, the goal of immunotoxin treatment is the direct killing of malignant cells. Because they are enzymatic proteins that act catalytically to kill cells, bacterial and plant toxins are often employed as the cell-killing component of immunotoxins. Here we provide background information into the structure-func­ tion relationships of toxins and discuss how they can be combined with cell-binding antibodies or other ligands to generate immunotoxins. Bacterial and plant toxins (e. g. , diphtheria toxin, Pseudomonas exotoxin and ricin) are among the most toxic substances known. However, because they bind to cell surface receptors that are present on most normal cells, unmodified toxins are generally useless as anti-cancer agents. To convert toxins into more selective agents, their binding domains are either eliminated or disabled and replaceq with cell­ binding antibodies that are tumor-selective.

Keywords

Bakterium bacteria clinical trial clinical trials immunotherapy leukemia lymphoma pharmacology poison protein proteins pseudomonas toxicity toxin tumor

Editors and affiliations

  • Arthur E. Frankel
    • 1
  1. 1.Hollings Cancer CenterMedical University of South CarolinaCharlestonUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-642-72153-3
  • Copyright Information Springer-Verlag Berlin Heidelberg 1998
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-72155-7
  • Online ISBN 978-3-642-72153-3
  • Series Print ISSN 0070-217X
  • Buy this book on publisher's site
Industry Sectors
Pharma
Biotechnology
Consumer Packaged Goods